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Congenital disorders, cancer, trauma, or other conditions of the genitourinary tract can lead to
signiﬁcant organ damage or loss of function, necessitating eventual reconstruction or replacement
of the damaged structures. However, current reconstructive techniques are limited by issues of tis-
sue availability and compatibility. Physicians and scientists have begun to explore tissue engineer-
ing and regenerative medicine strategies for repair and reconstruction of the genitourinary tract.
Tissue engineering allows the development of biological substitutes which could potentially restore
normal function. Tissue engineering efforts designed to treat or replace most organs are currently
being undertaken. Most of these efforts have occurred within the past decade. However, before
these engineering techniques can be applied to humans, further studies are needed to ensure the
safety and efﬁcacy of these new materials. Recent progress suggests that engineered urologic
tissues and cell therapy may soon have clinical applicability.
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1. INTRODUCTION
Congenital disorders, cancer, trauma, or other conditions of the genitourinary tract can lead to signiﬁcant
organ damage or loss of function, necessitating eventual reconstruction or replacement of the damaged
structures. However, current reconstructive techniques are limited by issues of tissue availability and
compatibility. These techniques use nonurologic host tissues (skin, gastrointestinal segments, or mucosa
from multiple body sites), donor tissues (cadaver fascia or cadaver or living donor kidney), heterologous
tissues (bovine collagen), or artiﬁcial materials (silicone, polyurethane, or polytetraﬂuoroethylene) to recon-
struct damaged organs. However, all of these materials can lead to signiﬁcant complications resulting from
immunologic rejection or functional mismatches between the native and implanted tissues.
In order to reduce or eliminate these complications, physicians and scientists have begun to explore
tissue engineering and regenerative medicine strategies for repair and reconstruction of the genitourinary
tract. Tissue engineering allows the development of biological substitutes which could potentially restore
normal function. This may involve the use of synthetic or natural matrices termed scaffolds. When used
alone, some scaffolds can facilitate the body’s natural ability to regenerate by directing new tissue growth.
Alternatively, scaffolds can be seeded with cells, and the resulting construct can be implanted into the
patient in order to restore the structure and function of damaged tissues and organs. In recent years,
novel methods of cell culture have been developed, and these methods allow autologous cells to be grown
ex vivo from a small sample of a patient’s own tissue. These cells can then be combined with an ap-
propriate scaffold material. This process may be able to generate the large amounts of tissue required for
genitourinary reconstruction without the donor site morbidity associated with grafting procedures. In ad-
dition, the engineered tissue would be biocompatible, and the risk of rejection would be eliminated.
In this paper, we will discuss various methods of generating engineered tissue. We will then focus
on development of tissue-engineering approaches that are designed speciﬁcally to repair male genital tissue
and restore normal appearance and function.
2. FUNDAMENTALS OF TISSUE ENGINEERING
2.1. Biomaterials
For cell-based tissue engineering, cells are generally seeded onto a synthesized scaffold. Biomaterials are
used to replicate the biologic and mechanical function of the native extracellular matrix (ECM) found in
tissues in the body by serving as an artiﬁcial ECM. Biomaterials can provide a three-dimensional space for
the cells to form into new tissues with appropriate structure and function and also can allow for the delivery
of cells and appropriate bioactive factors (e.g., cell adhesion peptides and growth factors) to desired sites
in the body [1]. As the majority of mammalian cell types are anchorage dependent and will die if no
cell-adhesion substrate is available, biomaterials provide a cell-adhesion substrate that can deliver cells to
speciﬁc sites in the body. Furthermore, bioactive signals, such as cell-adhesion peptides and growth factors,
can be loaded along with cells to help regulate cellular function.
Generally, three classes of biomaterials have been used for engineering tissues and organs: naturally
derived materials, such as collagen, acellular tissue matrices, such as bladder submucosa and small-intes-
tinal submucosa (SIS), and synthetic polymers, such as polyglycolic acid (PGA), polylactic acid (PLA),
and poly(lactic-co-glycolic acid) (PLGA). Naturally derived materials and acellular tissue matrices have
the potential advantage of biologic recognition, but synthetic polymers can be produced reproducibly on a
large scale with controlled properties of strength, degradation rate, and microstructure.
Collagen is the most abundant and ubiquitous structural protein in the body, and it may be readily
puriﬁedfrombothanimalandhumantissueswithanenzymetreatmentandsalt/acidextraction[2].Collagen
has long been known to exhibit minimal inﬂammatory and antigenic responses [3], and it has been approved
by the U.S. Food and Drug Administration for many types of medical applications [4]. This material can be
processed into a wide variety of structures such as sponges, ﬁbers, and ﬁlms [5–7].
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Acellular tissue matrices are collagen-rich matrices prepared by removing cellular components from
tissues. The matrices are often prepared by mechanical and chemical manipulation of a segment of bladder
tissue [8–11]. The matrices slowly degrade after implantation and are replaced and remodeled by ECM
proteins synthesized and secreted by transplanted or ingrowing cells. Acellular tissue matrices have been
proved to support cell ingrowth and regeneration of genitourinary tissues, including urethra and bladder,
with no evidence of immunogenic rejection [11, 12]. Because the structures of the proteins (e.g., collagen
and elastin) in acellular matrices are well conserved and normally arranged, the mechanical properties of
the acellular matrices are not signiﬁcantly different from those of native bladder submucosa [8].
Polyesters of naturally occurring α-hydroxy acids, including PGA, PLA, and PLGA, are widely
used in regenerative medicine. The degradation products of PGA, PLA, and PLGA are nontoxic, natural
metabolites that are eventually eliminated from the body in the form of carbon dioxide and water [13]. Be-
cause these polymers are thermoplastics, they can easily be formed into a three-dimensional scaffold with
a desired microstructure, gross shape, and dimension by various techniques, including molding, extrusion
[14], solvent casting [15], phase separation techniques, and gas-foaming techniques [16]. More recently,
techniques such as electrospinning have been used to quickly create highly porous scaffolds in various
conformations [17–20]. However, one drawback of the synthetic polymers is lack of biologic recognition.
2.2. Cells
Two main categories of stem cells are used in tissue engineering, pluripotent stem cells, and native pro-
genitor cells. Embryonic stem cells exhibit three unique properties: the ability to proliferate in an undif-
ferentiated but pluripotent state, the ability to differentiate into many specialized cell types, and the ability to
form clonal populations [21]. This makes them an attractive resource for regenerative medicine techniques.
They can be isolated by aspirating the inner cell mass from the embryo during the blastocyst stage [22].
Human embryonic stem cells have been shown to differentiate into cells from all three embryonic germ lay-
ers in vitro. The political controversy surrounding stem cells began in 1998 with the creation of human em-
bryonic stem cells derived from discarded embryos. In addition to the ethical dilemma surrounding the use
of embryonic stem cells, their clinical application is also limited, because they represent an allogenic re-
source and thus have the potential to evoke an immune response.
More recently, reports have been published of the transformation of adult cells isolated from organs
or bone marrow into pluripotent stem cells through a type of genetic “reprogramming”. Reprogramming is
a technique that involves dedifferentiation of adult somatic cells to produce patient-speciﬁc pluripotent stem
cells without the use of embryos. Cells generated by reprogramming would be genetically identical to the
somatic cells (and thus the patient who donated these cells) and would not be rejected. Mouse embryonic
ﬁbroblasts and adult mouse ﬁbroblasts have been reprogrammed into an “induced pluripotent state (iPS)”
[23]. When iPS cells were injected into mouse blastocysts, they contributed to a variety of cell types;
however, they were not identical to embryonic stem cells, as chimeras made from iPS cells did not result in
full-term pregnancies.
An alternate source of stem cells is the amniotic ﬂuid and placenta. Amniotic ﬂuid and the placenta
contain multiple partially differentiated cell types derived from the developing fetus. Isolated stem-cell
populations from these source have been shown to express embryonic and adult stem-cell markers [24].
The undifferentiated stem cells expand extensively without feeders and double every 36 hours. Unlike hu-
man embryonic stem cells, the amniotic ﬂuid stem cells do not form tumors in vivo. Lines maintained for
over 250 population doublings retained long telomeres and a normal karyotype. AFS cells are broadly mul-
tipotent.
An additional advantage in using native progenitor cells is that they can be obtained from the speciﬁc
organ to be regenerated, expanded, and used in the same patient without rejection in an autologous manner
[10, 25–41]. Bladder, ureter, and renal pelvis cells can equally be harvested, cultured, and expanded in a
similar fashion. Normal human bladder epithelial and muscle cells can be efﬁciently harvested from surgical
material, extensively expanded in culture, and their differentiation characteristics, growth requirements, and
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other biologic properties can be studied [33, 35, 36, 42–51]. Major advances in cell culture techniques have
beenmadewithinthepastdecade,andthesetechniquesmaketheuseofautologouscellspossibleforclinical
application.
When native cells are used for tissue reconstitution, donor tissue is dissociated into individual cells,
which are either implanted directly into the host or expanded in culture, attached to a support matrix, and
reimplanted after expansion. The implanted tissue can be heterologous, allogeneic, or autologous. Ideally,
this approach allows lost tissue function to be restored or replaced in toto and with limited complications
[31]. Native cells and tissues are usually preferable for reconstruction. In most cases, the replacement of lost
or deﬁcient tissues with functionally equivalent cells and tissues would improve the outcome for these pa-
tients. This goal may be attainable with the use of regenerative medicine techniques.
3. ENGINEERED PENILE PROSTHESES
Early procedures for penile reconstruction involved the use of rib cartilage as a stiffener; however, this
method fell out of favor due to poor functional and cosmetic results [52]. This was followed by the use
of extracavernosal acrylic stents, intracavernosal polypropylene rods, and ﬁnally silicone prostheses. While
current surgical treatment works well, there are signiﬁcant risks to the implantation of foreign materials into
the penis including infection and erosion which may necessitate removal [53].
Of the natural tissues in the human body, cartilage would serve as an ideal material for prosthesis
due to its rigidity and biochemical properties. Initial studies performed by Yoo et al. [54] have demonstrated
that cartilage rods could be produced by seeding bovine chondrocytes onto polyglycolic acid polymer rods
and implanting them into athymic nude mice. Compression, tension, and bending studies performed after
harvesting demonstrated that the cartilaginous structures were readily elastic and withstood high degrees of
pressure. All constructs showed mature well-formed chondrocytes.
Subsequent studies in rabbits by the same group [55] demonstrated the ability of cartilage rods to
function in vivo. Chondrocytes were harvested from rabbit ears and seeded onto biodegradable poly-L-
lactic acid coated polyglycolic acid polymer rods. They were then inserted into the corporal spaces of
rabbits. Harvested tissues demonstrated that the scaffold had fully degraded within two months, and at six
months, mature fully formed chondrocytes were present. There were no instances of infection or erosion of
these cartilage prostheses.
4. TISSUE ENGINEERING OF SPECIFIC PENILE STRUCTURES
4.1. Urethra
In men, the urethra is divided into three parts on the basis of anatomical location. The prostatic urethra
crosses through the prostate gland, the membranous urethra passes through the external urethral sphincter
and is the narrowest part of the urethra, and the membranous or penile urethra runs along the length of the
shaft of the penis through the corpus spongiosum. The urethral epithelium is primarily a continuation of the
bladder mucosa and is composed of transitional cells. As the urethra approaches the meatus, the mucosa
is made up of stratiﬁed columnar cells, followed by stratiﬁed squamous cells at the meatus itself. There
are small periurethral glands which secrete mucus along the length of the urethra which help to protect the
urethra from corrosive urine.
Congenital and acquired disorders of the urethra remain a challenge in the urology ﬁeld. Numerous
conditions including strictures, trauma, congenital defects, and cancer can often cause serious issues in
voiding requiring additional tissues for reconstruction and repair. Often, there is a lack of native urethral tis-
sue for adequate reconstruction requiring the use of tissue grafts of ﬂaps from other sources [56]. However,
the use of grafts and ﬂaps can lead to signiﬁcant complications, including stenosis, hair growth, and ﬁstula
formation [57, 58]. A variety of synthetic materials have also been proposed for use in urethral recon-
struction, including silicone, Teﬂon, and polyvinyl. These materials also have signiﬁcant complications
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including erosion, dislodgement, ﬁstula formation, stenosis, and calciﬁcation [59, 60]. For these reasons,
tissue-engineered biocompatible urethral segments would be a preferred material for urethroplasty [61].
4.1.1. Acellular Scaffolds in Urethral Repair
A number of acellular scaffolds have been used in animal models to facilitate the regeneration of urethral
tissue, including polyglycolic acid- and acellular collagen-based scaffolds made from small intestine and
bladder [62–66]. Biodegradable scaffolds such as polyglactin ﬁber mesh coated with polyhydroxybutyric
acid have been used to reconstruct urethras in dogs [65]. A four centimeter segment of canine urethra was
excised and replaced with this material. At 8–12 weeks after implantation, the acellular mesh had allowed
for regeneration of the urothelium, surrounding smooth muscle, and vasculature. Polyglactin ﬁber mesh
with hyaluronan benzyl ester has also been used in a similar fashion in a rabbit model. In this experiment,
degradation of the biomaterial was apparent around day three after implantation, and epitheliailzation and
collagen remodeling of the surrounding structures were seen within four weeks [67].
Native structures have also been used as scaffolds. Urethral reconstruction with tubularized peritone-
um has been attempted in a rabbit model, and this resulted in good epithelialization of the neourethra.
However, there was a high rate of ﬁstula formation with two of twelve animals developing ﬁstulas [68].
Initial studies using small bowel submucosa have also shown urethral regeneration supported by vascu-
larization and smooth muscle formation [64]. However, more recent studies of a commercially available
small bowel submucosal patch did not show any improvement in regeneration of the urethra versus native
healing in a rabbit model of urethral injury [69].
Bladder-derived acellular collagen matrix has proved to be a suitable graft for repair of urethral
defects [70]. In a rabbit model, segments of urethra have been resected and replaced with acellular collagen
scaffolds in an onlay fashion, and the animals were able to successfully void through the reconstructed
urethra [11]. This model has been applied clinically in patients with hypospadias who had undergone
previous repair and had a paucity of tissue for repeat reconstruction [71]. Cadaveric bladders were micro-
dissected, and the submucosal layer was isolated, washed, and decellularized. The collagen scaffold was
then trimmed to size and applied in an onlay fashion to the urethral plate using 6-0 absorbable sutures.
After a mean followup of nearly two years, three of four patients had good function and cosmesis. One pa-
tient developed a subglandular ﬁstula.
Similar collagen scaffolds have also been used in urethral stricture disease [72]. Scaffolds were pre-
pared in a similar fashion as above and applied to the urethral plate using 6-0 absorbable sutures. After
mean followup of 37 months, 24 of the 28 patients had a successful outcome with no decrease in ure-
thral caliber. The remaining four patients had a slight caliber decrease at the anastomotic sites on urethrog-
raphy. A subcoronal ﬁstula developed in one patient which closed spontaneously one year after repair.
Mean maximum urine ﬂow rate increased from a mean preoperative value of 9mL/sec to 19.7mL/sec
postoperatively. These studies demonstrate that collagen scaffolds appear to be beneﬁcial for patients with
abnormal urethral conditions. In followup with these patients three years later, they continued to do well
with no clinical changes from the initial postoperative period [73].
4.1.2. Cell-Seeded Scaffolds in Urethral Repair
Despite the successes in onlay repairs, it has been shown that tubularized urethral repairs with acellular
scaffolds are not feasible, as native cells are not able to fully incorporate into the circumferential scaffold
for defects greater than 0.5cm [74]. In these situations, cell seeded collagen scaffolds are preferable [75].
One of the initial limitations to using cell-based therapy for genitourinary applications had been the ability
to grow urothelial cells in large quantities. Normal urothelial cells could be harvested and grown but with
limited expansion potential. More recently, a number of techniques have been developed which allow for
the large-scale expansion of these cells without the need for enzymatic digestion or serum [76–78]. With
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the development of these techniques, it is now possible to collect autologous urothelial cells from patients,
expand them in culture, and return them to the host in quantities necessary for reconstructive procedures.
De Filippo et al. [75] have demonstrated the ability to perform circumferential urethroplasties using
cell-seeded scaffolds. Autologous bladder epithelium and smooth muscle from rabbits was harvested and
seeded onto tubularized collagen constructs. The entire urethra of male rabbits was excised, and urethro-
plasty was performed. Nine animals were reconstructed with cell-seeded scaffolds, and six animals were
reconstructed with acellular scaffolds. Serial urethrograms were performed showing a wide caliber urethra
in all animals implanted with the cell-seeded scaffold, while all animals repaired with the acellular scaffold
showed areas of signiﬁcant narrowing. Histologically, a transitional epithelial layer surrounded by increas-
inglyorganizedsmoothmusclebundleswasseeninthecell-seededscaffoldgroup.However,histologyfrom
the acellular scaffold group showed transitional cells surrounded by limited unorganized smooth muscle.
The cell-seeded scaffolds produced tissue which is histologically and functionally similar to native urethra.
Biocompatible uretheral stents have also been created using chondrocyte seeded polymer matrices
[79]. 10mm cartilaginous cylinder were developed with an outer diameter of 9mm from from polyglycolic
acid mesh coated with 50:50 polylactic-co-glycolic acid and were seeded with bovine chondrocytes and
implanted subcutaneously in nude mice. Biomechanical testing demonstrated that the cartilaginous cylin-
ders in each group were readily elastic and withstood high degrees of pressure.
4.2. Corporal Bodies
The anatomy of the penis is complex and composed of three separate cylinders. Two paired cylinders called
the corpora cavernosa make up the majority of the penis and are the primary structures involved in erectile
function. The corpora cavernosa consist of a network of large venous sinuses separated by dense connective
tissue called trabeculae. During erection, blood enters the corpora from the central artery into helicine
arteries and ﬁnally into the sinuses. These sinuses are later drained by smaller veins emptying into the
dorsal vein. The third cylinder is called the corpus spongiosum, and it houses the urethra. Each of the three
corpora is covered by a thick ﬁbrous covering called the tunica albuginea. All three of these cylinders are
covered by a thick membrane known as Buck’s fascia. Finally, Collie’s fascia, which is continuous with the
abdominal wall, covers the entire structure.
Extensive reconstructive procedures involving the corporal bodies may be needed in patients with
congenital malformation, malignancy, or trauma. Due to the shortage of autologous tissues, these surgical
procedures are typically staged and often utilize nongenital tissues as a grafting source. These procedures
have a high risk of complication due to infection, donor site morbidity, and graft failure [80, 81]. The
creation of alternative materials is a major challenge for phallic reconstruction due to the unique anatomical
architecture of the corporal bodies.
Although the corporal bodies only contain two primary cell types, smooth muscle, and endothelium,
engineering this tissue remains a challenge. Experiments by Kershen et al. [82] looked at the feasibility
of using human corporal smooth muscle cells for reconstructive procedures. Human corpus cavernosum
smooth muscle cells were harvested during surgical procedures, isolated, and cultured. They were then
seeded on polymer scaffolds and implanted subcutaneously into nude mice. Histology demonstrated smooth
muscle multilayers as well as ingrowth into the scaffold. Initial studies by Falke et al. were aimed at
replacing short segments of the corporal body by using natural collagen scaffolds and autologous cells
[83]. This was accomplished by harvesting donor rabbit corpora and decellularizing them. Human corporal
smooth muscle and endothelial cells [84, 85] were then seeded in a stepwise fashion, and the constructs
were implanted into athymic nude mice. Tissues were harvested at sequential time points after implantation
and demonstrated the presence of neovascularity in the sinusoidal spaces with increasing organization of
smooth muscle and collagen over time. Organ bath studies demonstrated the ability of these harvested
tissues to contract. No response was seen in unseeded control specimens.
This work was recently taken one step further by the same group. They demonstrated the ability to
bioengineer entire pendular penile corporal bodies in a rabbit model [86]. Decellularized donor corporal
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FIGURE 1: Using tissue engineering techniques to create entire penile corpora.
bodies were seeded with autologous smooth muscle and endothelial cells in a stepwise fashion (Figure 1).
Rabbits then underwent complete excision of the corporal bodies followed by implantation of seeded
scaffolds, unseeded scaffolds, or no construct. The group implanted with seeded scaffolds demonstrated
normal intracavernosal pressures within six months of surgery (Figure 2), and 10 out of 12 rabbits were
able to successfully mate with female rabbits, deﬁned as a positive vaginal swab for semen or pregnancy.
None of the unseeded scaffold group or negative controls was able to have successful intercourse.
To improve the cellular content of these bioengineered corporal bodies, corporal cells were seeded
dynamically onto acellular corporal tissue matrcies and placed in a mechanical bioreactor for 48 hours.
These constructs were then implanted into nude mice. Histology demonstrated that dynamically seeded
scaffolds lead to biochemically improved corporal tissues [87].
4.3. Tunica Albuginea
Patients with deformities of the penis, particularly Peyronie’s disease, can experience signiﬁcant pain and
functional problems due to plaque formation and curvature of the penis. Currently, diseases such as Pey-
ronie’s are treated with plaque excision or incision and grafting of the tunica albuginea with materials such
as small intestinal submucosa, fascia, and pericardium [88]. All of these materials have drawbacks, includ-
ing limited availability, donor site morbidity, and limited effectiveness. The use of a bioengineered tissue
would be able to overcome most of the limitations of current techniques while allowing for lasting results.
Schultheiss et al. [89] isolated porcine ﬁbroblasts from open fascia biopsies and seeded them on
decellularized collagen matrices. The seeded matrices were then cultivated in a bioreactor under continuous
multiaxial stress for 21 days. Static cultures without mechanical stress served as controls. Mechanically
strained cultures of ﬁbroblasts showed a homogeneous multilayer matrix inﬁltration and a regular cell align-
ment in the direction of strain axis after 7 days as well as increased production of extracellular matrix pro-
teins compared to the static control.
Similar work has been performed using an acellular bladder mucosal graft [90]. Acellular matrices
were constructed from pigs’ bladders by cell lysis. A segment of the tunica albuginea of nine rabbits was
excised, and the defect was covered with porcine bladder acellular matrix. Histology of the resected graft
showed collagen ﬁbers with many pores. Two months after implantation, the graft sites exhibited excellent
healing without contracture, and the fusion between the graft and the neighboring normal TA appeared to
be well established. There were no signiﬁcant histological differences between the implanted tunica and the
normal control tunica at 6 months after implantation.
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FIGURE 2: (a) Cavernosometry shows that all rabbits implanted with the bioengineered corpora after com-
plete pendular penile corporal excision had sufﬁcient intracorporal pressure (ICP) to attain erection. The
levels of ICP were comparable to native corpora. (b) Cavernosography shows a homogenous appearance of
corpora in the bioengineered group, similar to the native corpora, and multiple ﬁlling defects in the negative
control group.
5. CONCLUSION
Tissue-engineering efforts designed to treat or replace most organs are currently being undertaken. Most of
these efforts have occurred within the past decade. However, before these engineering techniques can be
appliedtohumans,furtherstudiesareneededtoensurethesafetyandefﬁcacyofthesenewmaterials.Recent
progress suggests that engineered urologic tissues and cell therapy may soon have clinical applicability.
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